Sarilumab
Sanofi,regeneron
[]
ab1676 #acr22 saphyr: sarilumab in refractory pmr
52wk sar 200 mg q2w + 14w taper gc v pbo+gc taper
primary endpt: sustain response at 52w
early term 2/2 covid, 117 pt
sar remission 28% vs pbo 10%, p=0.02
data consistent when removes crp data
pbo: more gcs 2/2 pmr flare 
Rheumatologist at Institute for Rheumatic and Autoimmune Disease at Overlook Hospital, proud Hopkins alum, health care advocate, Eagles fan entering Giants land